Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Status:
Active, not recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This study evaluates nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis
(DT/AF). Half of the participants will receive nirogacestat while the other half will receive
placebo.
Phase:
Phase 3
Details
Lead Sponsor:
SpringWorks Therapeutics SpringWorks Therapeutics, Inc.